Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC

PHASE3CompletedINTERVENTIONAL
Enrollment

512

Participants

Timeline

Start Date

September 15, 2018

Primary Completion Date

August 30, 2021

Study Completion Date

January 18, 2022

Conditions
Pancreatic Adenocarcinoma
Interventions
DRUG

eryaspase

L-asparaginase encapsulated in erythrocytes (red blood cells)

DRUG

Gemcitabine plus Abraxane

gemcitabine, Abraxane

DRUG

Irinotecan plus 5-FU plus leucovorin

irinotecan, 5-FU, leucovorin

Trial Locations (16)

10021

Weill Cornell Medicine, New York

Stony Brook University, Stony Brook

14263

Roswell Park Cancer Institute, Buffalo

14642

University of Rochester Medical Center, Rochester

20057

Georgetown University Hospital, Washington D.C.

27705

Duke University, Durham

29609

Institut de Cancerologie, Brest

33486

Boca Raton Regional Hospital, Boca Raton

55455

University of Minnesota Health Clinics and Surgery Center, Minneapolis

70121

Ochsner Clinic Foundation, New Orleans

85258

Arizona Cancer Center, Scottsdale

92835

St. Joseph Heritage Healthcare, Fullerton

95817

University of California Davis Medical Center, Sacramento

99208

Medical Oncology Associates, Spokane

02215

Beth Israel Deaconess Medical Center, Boston

W12 0HS

Hammersmith Hospital, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

ERYtech Pharma

INDUSTRY